|
Effet du palivizumab en prophylaxie sur la diminution des complications associées au virus respiratoire syncytial chez les enfants [Effect of palivizumab prophylaxis in reducing the complications associated with the respiratory syncytial virus in infants and young children] |
Breton M-C, Rossignol M, Fansi A, Jehanno C |
|
|
Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Breton M-C, Rossignol M, Fansi A, Jehanno C. Effet du palivizumab en prophylaxie sur la diminution des complications associées au virus respiratoire syncytial chez les enfants. [Effect of palivizumab prophylaxis in reducing the complications associated with the respiratory syncytial virus in infants and young children] Quebec: Institut national d'excellence en sante et en services sociaux (INESSS). 2016 Authors' conclusions The currently available data indicate that palivizumab is effective in reducing the risk of RSV hospitalization in preterm infants with or without CLD, non-preterm infants with CLD, infants with acyanotic congenital heart disease, infants in remote communities, and children with Down syndrome with risk factors. Few scientific data are available for the other outcome measures evaluated, and the results of the different studies are sometimes discordant. None of the data identified support the efficacy of palivizumab in children with cystic fibrosis. The efficacy of palivizumab in certain populations, such as preterm infants with CLD, infants in remote communities, children with Down syndrome and children with cystic fibrosis, is very sparsely documented, and the studies contain methodological limitations and various uncertainties. Furthermore, no studies were found concerning the efficacy of palivizumab prophylaxis compared to the administration of placebo or to no prophylaxis in immunocompromised infants or young children, those with a metabolic disease, a severe neuromuscular disorder affecting respiratory function or an anomaly of the upper respiratory tract affecting respiratory function, or those of a multiple birth who are healthy but whose twin qualifies for palivizumab. Indexing Status Subject indexing assigned by CRD MeSH Child; Humans; Infant; Palivizumab; Respiratory Syncytial Virus Infections; Respiratory Syncytial Virus, Human Country of organisation Canada English summary An English language summary is available. Address for correspondence Institut national d'excellence en santé et en services sociaux (INESSS), 1195 avenue Lavigerie, bureau 60 Québec (Québec) Canada, G1V 4N3
Email: inesss@inesss.qc.ca AccessionNumber 32017000010 Date abstract record published 03/01/2017 |
|
|
|